Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Reaches New 12-Month High at $41.91

Calliditas Therapeutics AB (publ) (NASDAQ:CALT)’s share price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $41.91 and last traded at $41.55, with a volume of 11806 shares. The stock had previously closed at $40.12.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on CALT shares. Jefferies Financial Group reiterated a “hold” rating and issued a $39.00 target price (down previously from $58.00) on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday, May 28th. Lifesci Capital lowered Calliditas Therapeutics AB (publ) from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 28th. Stifel Nicolaus restated a “hold” rating and issued a $40.00 target price (down from $55.00) on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday, May 28th. HC Wainwright reiterated a “neutral” rating and set a $39.00 price target on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday, May 28th. Finally, Citigroup restated a “neutral” rating and issued a $39.00 price objective on shares of Calliditas Therapeutics AB (publ) in a research note on Friday, May 31st. Five investment analysts have rated the stock with a hold rating, According to data from MarketBeat.com, Calliditas Therapeutics AB (publ) currently has a consensus rating of “Hold” and a consensus price target of $39.25.

Calliditas Therapeutics AB (publ) Trading Down 0.5 %

The company’s 50-day moving average is $39.32 and its 200-day moving average is $30.22. The company has a debt-to-equity ratio of 9.44, a quick ratio of 2.59 and a current ratio of 2.69. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -21.76 and a beta of 1.77.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.09. Calliditas Therapeutics AB (publ) had a negative return on equity of 212.04% and a negative net margin of 30.18%. The firm had revenue of $52.36 million during the quarter, compared to analysts’ expectations of $42.89 million. During the same period in the previous year, the business posted ($0.33) EPS. On average, research analysts predict that Calliditas Therapeutics AB will post -0.81 earnings per share for the current year.

Institutional Investors Weigh In On Calliditas Therapeutics AB (publ)

A hedge fund recently bought a new stake in Calliditas Therapeutics AB (publ) stock. Optiver Holding B.V. acquired a new position in shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 980 shares of the company’s stock, valued at approximately $25,000. Institutional investors and hedge funds own 2.83% of the company’s stock.

Calliditas Therapeutics AB (publ) Company Profile

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.